PLX icon

Protalix BioTherapeutics
PLX

Overview Fund Trends Analyst Outlook Journalist POV

15 hedge funds and large institutions have $2.12M invested in Protalix BioTherapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more capital invested

Capital invested by funds: $ → $

more ownership

Funds ownership: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

52% less funds holding

Funds holding: 31 → 15 (-16)

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 17

Holders
15
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$9K
Puts
$1K
Net Calls
Net Calls Change

Top Buyers

1
+$112K
2
+$100K
3
+$47.9K

Top Sellers

1
-$56.5K
2
-$42K
3
-$30K
4
JGC
J. Goldman & Co
New York
-$25K
5
MIH
Meitav Investment House
Israel
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$1.51M
2
$263K
3
$125K
4
$105K
5
$74K
6
$19K
7
$17K
8
$3.61K
9
$3K
10
–
11
–
12
–
13
–
14
–
15
–
16
–
17
–
18
–
19
–
20
–
21
–
22
–
23
–
24
–
25
–